Current management and use of oral immunotherapy in the United States for patients with peanut allergy
Michael S. Blaiss(Augusta University), Jay Liebermann(Le Bonheur Children's Hospital), N. Georgitseas(Navigant (Germany)), Brian Kwak, Daniel Petroni(Allergy Asthma Research Institute), Stephen A. Tilles(University of Washington), Marie Cassese, Ellen Zigmont
Cited by 14
Related Papers
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
|JAMA|2019|271
Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
|JCI Insight|2019|188
A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals
|EClinicalMedicine|2019|132
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
|New England Journal of Medicine|2023|129